Table 1.
Patient Characteristics Over Time.
| Date | Thyroglobulin (ng/ml) | Thyroid-Stimulating Hormone (mU/L)a | Weight (kg) | Significant Events |
|---|---|---|---|---|
| Nov 2014 | 90,400 | 0.1 | – | Post-thyroidectomy |
| Jan 2015 | 67,500 | 6.64 | – | Post 1st RAI |
| Apr 2015 | 25,004 | 2.04 | 71 | Post 2nd RAI |
| Jan 2016 | 9,400 | 0.65 | – | Post 4th RAI |
| Jun 2016 | 7,330 | 0.06 | – | – |
| Oct 2016 | 8,071 | 0.09 | – | – |
| Feb 2017 | 5,802 | 0.02 | – | PD - palliative radiotherapy |
| May 2017 | 3,470 | 0.04 | – | – |
| July 2017 | – | – | – | PD - further radiotherapy |
| Aug 2017 | 119,200 | 0.02 | – | Lenvatinib started |
| Sep 2017 | 132,300 | 0.13 | – | – |
| Nov 2017 | 10,493 | 0.43 | 66 | – |
| Jan 2018 | 6,660 | 0.53 | 67 | – |
| Oct 2018 | 10,451 | 11.27 | 67 | – |
| Jan 2019 | 7,328 | 0.12 | 69 | – |
| Mar 2019 | 8,246 | 0.08 | 68 | – |
| May 2019 | 11,537 | 0.07 | 68 | – |
| Jul 2019 | 16,372 | 0.11 | 69 | – |
| Feb 2020 | 20,327 | 3.75 | 76 | – |
aThe normal range for thyroid-stimulating hormone is 0.34–5.4 mU/L.
RAI, radioactive iodine treatment; PD, progressive disease.